RGH 0205: RN given refers to all (L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 3033953 |
| CHEMBL ID | 2105488 |
| CHEBI ID | 159125 |
| SCHEMBL ID | 62515 |
| SCHEMBL ID | 15532089 |
| MeSH ID | M0133010 |
| Synonym |
|---|
| thymotrinanum [inn-latin] |
| arg-lys-asp |
| thymotrinan [inn] |
| arginyl-lysyl-aspartic acid |
| timotrinan [inn-spanish] |
| l-aspartic acid, n-(n(sup 2)-l-arginyl-l-lysyl)- |
| rgh 0205 |
| n-(n(sup 2)-l-arginyl-l-lysyl)-l-aspartic acid |
| rgh-0205 |
| thymotrinan |
| 85465-82-3 |
| CHEBI:159125 |
| (2s)-2-[[(2s)-6-amino-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]butanedioic acid |
| CHEMBL2105488 |
| thymotrinanum |
| timotrinan |
| unii-29oe04a6c9 |
| 29oe04a6c9 , |
| SCHEMBL62515 |
| DTXSID60234687 |
| SCHEMBL15532089 |
| thymopoietin ii (32-34) |
| (s)-2-((s)-6-amino-2-((s)-2-amino-5-guanidinopentanamido)hexanamido)succinic acid |
| l-arginyl-l-lysyl-l-aspartic acid |
| rgh 0205; tp 3 |
| Q27254434 |
| HY-106765 |
| CS-0026503 |
| AKOS040754202 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " toxicity test on Wobe:BEAGLE dogs given daily doses of 6, 20 and 60 mg/kg of either test compound, no adverse reaction occurred." | ( Preclinical toxicity studies with two thymopoietin-like peptides. Bodrogligeti, I; Cholnoky, E; Iván, E; Juhász-Nagy, A; Német, L, 1985) | 0.27 |
| Class | Description |
|---|---|
| oligopeptide | A peptide containing a relatively small number of amino acids. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (83.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||